Anne Lesage, Chief Early Development Officer at Pharvaris N.V. (NASDAQ:PHVS), filed a Form 4 on September 14, 2026, disclosing the exercise of stock options and sale of common stock on September 10, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Lesage exercised options covering 30,000 shares of common stock at an exercise price of $8.05 per share on September 10, 2026.
  • Shares sold: 30,000 shares of common stock were disposed of at a weighted average sale price of $38.3028, with individual transaction prices ranging from $38.00 to $38.90.
  • Planned transaction: According to the filing, the exercise and sale were part of a scheduled 10b5-1 trading plan.
  • Remaining ownership: Following the transactions, Lesage directly holds 56,450 shares of common stock.
  • Derivative securities: An additional stock option transaction (code M) covered 8,000 shares, with 15,000 stock options remaining after the reported transactions.
  • Vesting schedule: The filing states that 25% of the relevant option vested on April 6, 2024, with the remaining shares vesting in 1/48 monthly installments thereafter.

Pharvaris Officer Executes Cashless Option Exercise Under 10b5-1 Plan

According to the Form 4 filed with the SEC, Anne Lesage, serving as Chief Early Development Officer at Pharvaris N.V., conducted a cashless exercise transaction on September 10, 2026. The filing indicates that 30,000 shares were acquired via an option exercise (transaction code M) at a price of $8.05 per share, and those same 30,000 shares were simultaneously sold (transaction code S) at a weighted average price of $38.3028. The filing notes the sales were made "in connection with the exercise of stock options in a cashless exercise transaction."

The filing discloses that the reported sale price of $38.3028 represents a weighted average across multiple transactions executed on the same date, with individual prices ranging from $38.00 to $38.90. Lesage, through her attorney-in-fact Marnus Nel, undertook to provide full information regarding the number of shares sold at each separate price upon request by the issuer, any security holder, or SEC staff. Following these transactions, Lesage directly holds 56,450 shares of Pharvaris common stock, compared to 86,450 shares held prior to the reported sale.

Separately, Table II of the filing records an option exercise (code M) of 8,000 shares underlying a stock option with an exercise price of $8.05 and an expiration date of April 6, 2033. After that transaction, 15,000 stock options remain directly held by Lesage. The filing states that 25% of the option vested on April 6, 2024, with the remaining portion vesting in 1/48 monthly installments thereafter. All transactions described in the filing are characterized as scheduled activities conducted pursuant to a Rule 10b5-1 trading plan.

What Was Disclosed

The filing reports Anne Lesage's exercise of options and sale of 30,000 Pharvaris common shares on September 10, 2026, under a pre-established 10b5-1 plan, resulting in direct beneficial ownership of 56,450 shares and 15,000 remaining stock options.